The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis

Non-small cell lung cancer (NSCLC) remains a problem worldwide due to its rapid progression and low rate of response to treatment. The heterogeneity of these tumors observed in histopathology exam but also in the mutational status and gene expression pattern makes this malignancy difficult to treat in clinic. The present study investigated the effect of miR-21 and let-7 family members as prognostic biomarkers in NSCLC patients based on the results published in different studies regarding this subject until March 2019. The analysis revealed that these two transcripts are steady biomarkers for prediction of patient outcome or survival. Upregulated expression of miR-21 is associated with poor outcome of patients with NSCLC [HR = 1.87, 95% CI = (1.41, 2.47), p < 0.001]. The analysis regarding let-7 family, specifically let-7a/b/e/f, revealed that downregulated expression of these transcripts predicts poor outcome for NSCLC patients [HR = 2.61, 95% CI = (1.58, 4.30), p < 0.001]. Besides, the reliability of these microRNAs is reflected in the fact that their prognostic significance is constant given the different sample types (tissue, FFPE tissue, serum, serum/plasma or exosomes) used in the selected studies.

[1]  L. Crinò,et al.  Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer , 2019, Journal of clinical medicine.

[2]  G. Calin,et al.  CRISPR-based RNA editing: diagnostic applications and therapeutic options , 2019, Expert review of molecular diagnostics.

[3]  Yiping Zhu,et al.  miR-21-5p induces cell proliferation by targeting TGFBI in non-small cell lung cancer cells , 2018, Experimental and therapeutic medicine.

[4]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[5]  I. Berindan‐Neagoe,et al.  Overview upon miR-21 in lung cancer: focus on NSCLC , 2018, Cellular and Molecular Life Sciences.

[6]  D. Takai,et al.  MicroRNA-21 in cancer-associated fibroblasts supports lung adenocarcinoma progression , 2018, Scientific Reports.

[7]  A. Magnano,et al.  LncRNA UCA1, Upregulated in CRC Biopsies and Downregulated in Serum Exosomes, Controls mRNA Expression by RNA-RNA Interactions , 2018, Molecular therapy. Nucleic acids.

[8]  Jian-zhong Wu,et al.  MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment , 2018, Journal of Cancer Research and Clinical Oncology.

[9]  I. Lossos,et al.  MiR-181 family-specific behavior in different cancers: a meta-analysis view , 2018, Cancer and Metastasis Reviews.

[10]  Yi Zhang,et al.  Correlation between microRNA expression, clinicopathological characteristics, and prognosis in patients with Non‐small cell Lung Cancer: A retrospective study , 2017, Thoracic cancer.

[11]  Y. Li,et al.  MiR-146b-5p functions as a suppressor miRNA and prognosis predictor in non-small cell lung cancer , 2017, Journal of Cancer.

[12]  G. Calin,et al.  Non-coding RNAs: the cancer genome dark matter that matters! , 2017, Clinical chemistry and laboratory medicine.

[13]  Qi Liu,et al.  Prognostic and Predictive Effects of Positive Lymph Node Number or Ratio in NSCLC , 2017, Scientific Reports.

[14]  H. Iinuma,et al.  Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer. , 2017, Oncology letters.

[15]  Zhi-tu Zhu,et al.  Role of microRNA-21 in radiosensitivity in non-small cell lung cancer cells by targeting PDCD4 gene , 2017, Oncotarget.

[16]  Yunhong Yin,et al.  Non-small cell lung cancer associated microRNA expression signature: integrated bioinformatics analysis, validation and clinical significance , 2017, Oncotarget.

[17]  Weijia Xie,et al.  Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer , 2016, Oncotarget.

[18]  A. Kalmár,et al.  Comparison of Circulating miRNAs Expression Alterations in Matched Tissue and Plasma Samples During Colorectal Cancer Progression , 2017, Pathology & Oncology Research.

[19]  P. Ruestow,et al.  Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. , 2016, Lung cancer.

[20]  L. Pan,et al.  MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN , 2016, Oncotarget.

[21]  K. Wang,et al.  The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis , 2016, Oncotarget.

[22]  George A. Calin,et al.  microRNA Therapeutics in Cancer — An Emerging Concept , 2016, EBioMedicine.

[23]  D. Bartsch,et al.  MicroRNAs let7 expression in thyroid cancer: correlation with their deputed targets HMGA2 and SLC5A5 , 2016, Journal of Cancer Research and Clinical Oncology.

[24]  G. Dy,et al.  Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options@@@Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options , 2016 .

[25]  M. Cañadas-Garre,et al.  PTEN and PI3K/AKT in non-small-cell lung cancer. , 2015, Pharmacogenomics.

[26]  Yi-long Wu,et al.  Differences in driver genes between smoking‐related and non–smoking‐related lung cancer in the Chinese population , 2015, Cancer.

[27]  A. Nicholson,et al.  Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  H. Cai,et al.  Inhibition of c-Myc by let-7b mimic reverses mutidrug resistance in gastric cancer cells. , 2015, Oncology reports.

[29]  F. Slack,et al.  Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation , 2015, Cell cycle.

[30]  G. Calin,et al.  Molecular Pathways Molecular Pathways : microRNAs , Cancer Cells , and Microenvironment , 2014 .

[31]  Xiao-guang Liu,et al.  Differential Expression of miR-125a-5p and let-7e Predicts the Progression and Prognosis of Non-Small Cell Lung Cancer , 2014, Cancer investigation.

[32]  I. Sheyhidin,et al.  HMGA2 is down‐regulated by microRNA let‐7 and associated with epithelial–mesenchymal transition in oesophageal squamous cell carcinomas of Kazakhs , 2014, Histopathology.

[33]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[34]  S. Sarkar,et al.  MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression. , 2014, Cancer letters.

[35]  Shaolei Li,et al.  MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. , 2014, Cancer letters.

[36]  M. Fabbri,et al.  MicroRNAs and other non-coding RNAs as targets for anticancer drug development , 2013, Nature Reviews Drug Discovery.

[37]  A. Schetter,et al.  Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. , 2013, Cancer research.

[38]  Z. Jing,et al.  Overexpression of miRNA-21 promotes radiation-resistance of non-small cell lung cancer , 2013, Radiation Oncology.

[39]  Jian Luo,et al.  Overexpression of miRNA-21 promotes radiation-resistance of non-small cell lung cancer. , 2013, Radiation oncology.

[40]  M. Kuo,et al.  Function and regulation of let-7 family microRNAs. , 2012, MicroRNA.

[41]  P. Korošec,et al.  let-7b and miR-126 Are Down-Regulated in Tumor Tissue and Correlate with Microvessel Density and Survival Outcomes in Non–Small–Cell Lung Cancer , 2012, PloS one.

[42]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[43]  Michael A. McDaniel,et al.  Publication Bias in the Organizational Sciences , 2012 .

[44]  Xiao-guang Liu,et al.  Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients , 2012, Medical Oncology.

[45]  Xiao-guang Liu,et al.  miRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes , 2012, Journal of Cancer Research and Clinical Oncology.

[46]  Matthew D. Wilkerson,et al.  Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation , 2012, PloS one.

[47]  Y. Shu,et al.  MiRNA-21 , 2012, Cancer biology & therapy.

[48]  Jing Liu,et al.  MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN , 2012, Molecular and Cellular Biochemistry.

[49]  Xiao-guang Liu,et al.  High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer , 2012, Medical Oncology.

[50]  W. De,et al.  Prognostic significance of serum miRNA‐21 expression in human non‐small cell lung cancer , 2011, Journal of surgical oncology.

[51]  George A Calin,et al.  MicroRNA profiling in cancer. , 2011, Clinical science.

[52]  Vidar Skaug,et al.  The Association of MicroRNA Expression with Prognosis and Progression in Early-Stage, Non–Small Cell Lung Adenocarcinoma: A Retrospective Analysis of Three Cohorts , 2011, Clinical Cancer Research.

[53]  M. Kahn,et al.  A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  Y. Shu,et al.  MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis , 2011, Journal of Cancer Research and Clinical Oncology.

[55]  Jane J. Sohn,et al.  MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. , 2010, Cancer research.

[56]  Christopher R. Cabanski,et al.  Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types , 2010, Clinical Cancer Research.

[57]  Á. Zaballos,et al.  Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival , 2010, European Respiratory Journal.

[58]  Yingdong Zhao,et al.  MicroRNA Expression Differentiates Histology and Predicts Survival of Lung Cancer , 2010, Clinical Cancer Research.

[59]  M. Fabbri,et al.  Epigenetics and miRNAs in human cancer. , 2010, Advances in genetics.

[60]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[61]  J. Wan,et al.  The effects of HIF-1alpha on gene expression profiles of NCI-H446 human small cell lung cancer cells , 2009, Journal of experimental & clinical cancer research : CR.

[62]  S. De Flora,et al.  Relationships of microRNA expression in mouse lung with age and exposure to cigarette smoke and light , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[63]  A. Schetter,et al.  MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers , 2009, Proceedings of the National Academy of Sciences.

[64]  Vassilis Georgoulias,et al.  Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. , 2008, Clinical chemistry.

[65]  Ping Yang,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[66]  F. Slack,et al.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer , 2008, Cell cycle.

[67]  Phillip A Sharp,et al.  Suppression of non-small cell lung tumor development by the let-7 microRNA family , 2008, Proceedings of the National Academy of Sciences.

[68]  J. Steitz,et al.  Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation , 2007, Science.

[69]  Anindya Dutta,et al.  The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. , 2007, Genes & development.

[70]  David P. Bartel,et al.  Supporting Online Material Materials and Methods Fig. S1 Tables S1 and S2 References Database S1 Disrupting the Pairing between Let-7 and Hmga2 Enhances Oncogenic Transformation , 2022 .

[71]  Stefano Monti,et al.  Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[73]  D. Neuberg,et al.  Familial cancer associated with a polymorphism in ARLTS1. , 2005, The New England journal of medicine.

[74]  Takayuki Kosaka,et al.  Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.

[75]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[76]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[77]  Kenneth M. Yamada,et al.  Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. , 2001, Journal of cell science.